Ipamorelin/CJC-1295 Blend — Research, Dosing & Price Guide

The Ipamorelin/CJC-1295 blend combines two complementary GH-releasing peptides in a single vial: Ipamorelin (a GHRP acting on the ghrelin receptor) and CJC-1295 without DAC (a GHRH analog acting on the GHRH receptor). This combination is the gold standard for GH optimization, producing synergistic GH pulses 3–5 times greater than either peptide alone.

This blend exploits the well-established GHRH + GHRP synergy. CJC-1295 (no DAC) binds to GHRH receptors on pituitary somatotrophs, priming them for GH release by increasing intracellular cAMP and sensitizing calcium channels. Simultaneously, Ipamorelin activates GHS-R1a receptors through a separate phospholipase C/IP3 pathway, directly triggering GH vesicle exocytosis. Ipamorelin also suppresses somatostatin (GH's natural brake), removing the inhibitory tone that would otherwise limit the GHRH-driven release. The net effect is a dramatically amplified, pulsatile GH release pattern that closely resembles — but exceeds — youthful physiological GH secretion. The blend preserves Ipamorelin's selectivity (no cortisol or prolactin elevation) while maximizing GH output.

• The GHRH + GHRP synergy has been documented since the 1990s — Bowers et al. showed combined administration produces GH peaks 3–10x greater than either alone (Endocrine Reviews)
• Individual component studies support the combination: Ipamorelin's selectivity (Raun et al., 1998) paired with CJC-1295's extended GHRH activity
• Clinical observations suggest the blend protocol is the most effective non-exogenous-GH approach to elevating IGF-1 levels
• Body composition studies in aging populations show GH optimization via secretagogue combinations improves lean mass, reduces visceral fat, and enhances skin quality
• The synergy is pharmacologically well-understood: convergent signaling on different intracellular pathways in the same somatotroph cell

• Standard dose: 100–300 mcg of each peptide (combined in one injection), 1–3 times daily
• Common blend ratios: 1:1 (e.g., 100 mcg Ipamorelin + 100 mcg CJC-1295 per injection)
• Optimal timing: upon waking (fasted), post-workout, and before bed
• Must be administered on an empty stomach — wait 2+ hours after eating, 30 minutes before eating
• Cycle: 8–16 weeks on, 4 weeks off
• Pre-bed dose is highest priority — amplifies the natural nocturnal GH surge during deep sleep
• Subcutaneous injection into abdominal fat preferred

Known Side Effects

• Mild head rush or lightheadedness after injection (especially fasted)
• Mild water retention in first 1–2 weeks
• Injection site reactions
• Tingling/numbness in extremities (GH-mediated paresthesia)
• Vivid dreams and deeper sleep
• CJC-1295 may cause transient facial flushing

Safety Profile

The blend inherits the safety profiles of both individual components. Ipamorelin contributes selectivity and minimal hormonal disruption; CJC-1295 (no DAC) has a short half-life (~30 minutes) that produces pulsatile rather than continuous GHRH stimulation. Together, they maintain physiological GH regulation through preserved somatostatin feedback. Monitor IGF-1, fasting glucose, and HbA1c every 3–6 months. Same contraindications as individual components: active cancer, uncontrolled diabetes, pituitary tumors, pregnancy. Well-suited for long-term intermittent use.

Week 1: Improved sleep quality — deeper, more restorative. Mild water retention. Week 2–4: Enhanced recovery, better skin hydration, improved energy. Body composition improvements begin. Weeks 5–8: Measurable fat loss and lean mass gains. Skin quality visibly improved. IGF-1 levels elevated significantly. Weeks 9–16: Peak benefits across all domains. This blend typically produces the most comprehensive GH-optimization results available without exogenous GH. Benefits gradually taper over 4–8 weeks after cycling off.

Prices sourced from peptides.gg marketplace. Prices may vary.